SCHEMBL4911969

SCHEMBL4911969

CCCCOc1nccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
CYP2D6 P10635 5/20 0.40
CYP3A4 P08684 3/20 0.40
PLA2G4A P47712 3/20 0.40
CYP1A2 P05177 4/20 0.39
CCNB2 O95067 1/20 0.37
CCNE2 O96020 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
CCNB3 Q8WWL7 1/20 0.37
FBP1 P09467 1/20 0.37
PKM P14618 1/20 0.36
HRH2 P25021 1/20 0.36
HRH1 P35367 1/20 0.36
CYP19A1 P11511 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919846 0.89
SCHEMBL2658806 0.81 L3MBTL1 (0.55) L3MBTL1PLA2G4ACCNB2CCNE2CDK1
SCHEMBL577582 0.80
SCHEMBL9370817 0.79 KDM1A (0.40) L3MBTL1FBP1
SCHEMBL15547487 0.79 L3MBTL1 (0.35) L3MBTL1FBP1PKM
SCHEMBL9871802 0.79 L3MBTL1 (0.35) L3MBTL1FBP1PKM
SCHEMBL9270136 0.78 SLC2A1 (0.42) CYP2D6CYP3A4PLA2G4ACYP1A2HRH2
Bromide SCHEMBL27458288 0.78
SCHEMBL2628935 0.77 HRH3 (0.40) CYP2D6CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL737110 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PFIZER INC. 2008-08-21 US disclosed
EP-1866317-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-19 EP disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed
US-5519040-A Substituted thiazole sulfonamides as antiglaucoma agents ALLERGAN (US) 1996-05-21 US disclosed
WO-1995029904-A1 SUBSTITUTED THIAZOLE SULFONAMIDES AS ANTIGLAUCOMA AGENTS ALLERGAN (US) 1995-11-09 WO disclosed
US-RE29843-E Substituted thiazoles and flavoring processes and products produced thereby INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1978-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PF4, TBXA2R, P2RY4 L3MBTL1 3994/4885CYP2D6 113/4885CYP3A4 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.